by EpicentRx | Feb 9, 2023 | Conferences
November 2022, Boston, Massachusetts Oral Presentation: RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases Evaluate strategy and execution of drug design and translational development Understanding relevant pathology...
by EpicentRx | Feb 9, 2023 | Conferences
November 2022, San Diego, California Oral Presentation: The NLRP3 inhibitor RRx-001 crosses the blood brain barrier and alleviates neuroinflammation in experimental models of Parkinson’s disease
by EpicentRx | Feb 6, 2023 | Blog
For EpicentRx, 2023 has already been transforming—as in transforming growth factor beta (TGF-ß), which is overexpressed in most tumors. TGF-ß is a cytokine, a small protein that cells use to communicate with each other, normally released in wound areas following...
